Patents by Inventor Jamie Singer
Jamie Singer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11974980Abstract: A method of treating a pediatric cancerous solid tumor in a mammalian subject is disclosed that comprises intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor. Another contemplated method comprises the steps of intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor and systemically administering a tumor-inhibiting effective amount of a systemic anti-cancer medication that provides synergistic cytotoxicity with the halogenated xanthene. The two administrations can occur concurrently, or one prior to the other.Type: GrantFiled: June 10, 2021Date of Patent: May 7, 2024Assignees: Provectus Pharmatech, Inc., UTI Limited PartnershipInventors: Jamie Singer, Eric A. Wachter, Satbir Thakur, Lucy Swift, Chunfen Zhang, Mohit Jain, Aru Narendran
-
Patent number: 11426379Abstract: A treatment for inflammatory dermatoses, such as psoriasis and atopic dermatitis (eczema), is disclosed that utilizes topical administration of a halogenated xanthene, such as rose bengal, together with administration of one or more complementary targeted systemic dermatology therapies, preferably a therapy that addresses the inflammatory pathway and is other than an NSAID that is a COX-1 and/or COX-2 inhibitor. Examples of complementary targeted systemic therapeutic ingredients include: corticosteroids, including betamethasone dipropionate and fluocinonide; dithranol; vitamin D analogs, including calcipotriol; and retinoids, non-biologics including methotrexate, ciclosporin, hydroxycarbamide, and fumarates including dimethyl fumarate; as well as one or more biologics, including antibodies or paratope-containing antibody portions to TNF-?, antibodies to pro-inflammatory cytokines interleukin-12, interleukin-23 and interleukin-17, and TNF inhibitors.Type: GrantFiled: November 29, 2018Date of Patent: August 30, 2022Assignees: Provectus Pharmatech, Inc., The Rockefeller UniversityInventors: James G. Krueger, Sandra Garcet, Jamie Singer, Eric A. Wachter
-
Publication number: 20220054449Abstract: A treatment for inflammatory dermatoses, such as psoriasis and atopic dermatitis (eczema), is disclosed that utilizes topical administration of a halogenated xanthene, such as rose bengal, together with administration of one or more complementary targeted systemic dermatology therapies, preferably a therapy that addresses the inflammatory pathway and is other than an NSAID that is a COX-1 and/or COX-2 inhibitor. Examples of complementary targeted systemic therapeutic ingredients include: corticosteroids, including betamethasone dipropionate and fluocinonide; dithranol; vitamin D analogs, including calcipotriol; and retinoids, non-biologics including methotrexate, ciclosporin, hydroxycarbamide, and fumarates including dimethyl fumarate; as well as one or more biologics, including antibodies or paratope-containing antibody portions to TNF-?, antibodies to pro-inflammatory cytokines interleukin-12, interleukin-23 and interleukin-17, and TNF inhibitors.Type: ApplicationFiled: September 3, 2021Publication date: February 24, 2022Applicants: The Rockefeller University, Provectus Pharmatech, Inc.Inventors: James G. Krueger, Sandra Garcet, Jamie Singer, Eric A. Wachter
-
Publication number: 20210308091Abstract: A method of treating a pediatric cancerous solid tumor in a mammalian subject is disclosed that comprises intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor. Another contemplated method comprises the steps of intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor and systemically administering a tumor-inhibiting effective amount of a systemic anti-cancer medication that provides synergistic cytotoxicity with the halogenated xanthene. The two administrations can occur concurrently, or one prior to the other.Type: ApplicationFiled: June 10, 2021Publication date: October 7, 2021Applicants: Provectus Pharmatech, Inc., UTI Limited PartnershipInventors: Jamie Singer, Eric A. WACHTER, Satbir THAKUR, Lucy SWIFT, Chunfen ZHANG, Mohit JAIN, Aru NARENDRAN
-
Patent number: 11058664Abstract: A method of treating a pediatric cancerous solid tumor in a mammalian subject is disclosed that comprises intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor. Another contemplated method comprises the steps of intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor and systemically administering a tumor-inhibiting effective amount of a systemic anti-cancer medication that provides synergistic cytotoxicity with the halogenated xanthene. The two administrations can occur concurrently, or one prior to the other.Type: GrantFiled: May 15, 2019Date of Patent: July 13, 2021Assignees: Provectus Pharmatech, Inc., UTI Limited PartnershipInventors: Jamie Singer, Eric A. Wachter, Satbir Thakur, Lucy Swift, Chunfen Zhang, Mohit Jain, Aru Narendran
-
Publication number: 20190350893Abstract: A method of treating a pediatric cancerous solid tumor in a mammalian subject is disclosed that comprises intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor. Another contemplated method comprises the steps of intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor and systemically administering a tumor-inhibiting effective amount of a systemic anti-cancer medication that provides synergistic cytotoxicity with the halogenated xanthene. The two administrations can occur concurrently, or one prior to the other.Type: ApplicationFiled: May 15, 2019Publication date: November 21, 2019Applicant: Provectus Pharmatech, Inc.Inventors: Jamie Singer, Eric A. Wachter, Lucy Swift, Chunfen Zhang, Tanya Trippett, Aru Narendran
-
Patent number: 10471144Abstract: A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.Type: GrantFiled: November 6, 2017Date of Patent: November 12, 2019Assignees: Provectus Pharmatech, Inc., Pfizer, Inc.Inventors: Craig J. Eagle, H. Craig Dees, Eric A. Wachter, Jamie Singer
-
Publication number: 20190160039Abstract: A treatment for inflammatory dermatoses, such as psoriasis and atopic dermatitis (eczema), is disclosed that utilizes topical administration of a halogenated xanthene, such as rose bengal, together with administration of one or more complementary targeted systemic dermatology therapies, preferably a therapy that addresses the inflammatory pathway and is other than an NSAID that is a COX-1 and/or COX-2 inhibitor. Examples of complementary targeted systemic therapeutic ingredients include: corticosteroids, including betamethasone dipropionate and fluocinonide; dithranol; vitamin D analogs, including calcipotriol; and retinoids, non-biologics including methotrexate, ciclosporin, hydroxycarbamide, and fumarates including dimethyl fumarate; as well as one or more biologics, including antibodies or paratope-containing antibody portions to TNF-?, antibodies to pro-inflammatory cytokines interleukin-12, interleukin-23 and interleukin-17, and TNF inhibitors.Type: ApplicationFiled: November 29, 2018Publication date: May 30, 2019Inventors: James G. Krueger, Sandra Garcet, Jamie Singer, Eric A. Wachter
-
Publication number: 20190030074Abstract: A cancer immunotherapy method is disclosed in which “induced immune anticancer agents” are isolated after being induced in an animal host by intralesional (IL) administration of a halogenated xanthene tumor-ablative compound into a solid cancerous tumor of that host animal. A sample of the induced immune anticancer agents is removed (collected) from the tumor-bearing host, banked if desired, cultured and preferentially expanded to form an immunologically-effective enriched tumor-specific immune anticancer agent composition. That composition is reintroduced in to the host from which the predecessor induced immune anticancer agents were taken, or into another immunologically suitable host in need.Type: ApplicationFiled: October 2, 2018Publication date: January 31, 2019Applicants: Provectus Pharmatech, Inc., H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: Jamie SINGER, Eric A. WACHTER, Amod SARNAIK, Shari PHILON-THOMAS, Hao LIU
-
Patent number: 10130658Abstract: A cancer immunotherapy method is disclosed in which “induced immune anticancer agents” are isolated after being induced in an animal host by intralesional (IL) administration of a halogenated xanthene tumor-ablative compound into a solid cancerous tumor of that host animal. A sample of the induced immune anticancer agents is removed (collected) from the tumor-bearing host, banked if desired, cultured and preferentially expanded to form an immunologically-effective enriched tumor-specific immune anticancer agent composition. That composition is reintroduced in to the host from which the predecessor induced immune anticancer agents were taken, or into another immunologically suitable host in need.Type: GrantFiled: December 18, 2015Date of Patent: November 20, 2018Assignees: Provectus Pharmatech, Inc., H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: Jamie Singer, Eric Wachter, Amod Sarnaik, Shari Pilon-Thomas, Hao Liu
-
Publication number: 20180055926Abstract: A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.Type: ApplicationFiled: November 6, 2017Publication date: March 1, 2018Applicants: Provectus Pharmatech, Inc., Pfizer, Inc.Inventors: Craig J. EAGLE, H. Craig DEES, Eric A. WACHTER, Jamie SINGER
-
Patent number: 9839688Abstract: A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.Type: GrantFiled: June 24, 2015Date of Patent: December 12, 2017Assignees: Provectus Pharmatech, Inc., Pfizer, Inc.Inventors: Craig J. Eagle, H. Craig Dees, Eric A. Wachter, Jamie Singer
-
Patent number: 9808524Abstract: A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.Type: GrantFiled: June 24, 2015Date of Patent: November 7, 2017Assignees: Provectus Pharmatech, Inc., Pfizer, Inc.Inventors: Craig J. Eagle, H. Craig Dees, Eric A. Wachter, Jamie Singer
-
Patent number: 9750807Abstract: A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.Type: GrantFiled: June 24, 2015Date of Patent: September 5, 2017Assignees: Provectus Pharmatech, Inc., Pfizer, Inc.Inventors: Craig J. Eagle, H. Craig Dees, Eric A. Wachter, Jamie Singer
-
Publication number: 20170173079Abstract: A cancer immunotherapy method is disclosed in which “induced immune anticancer agents” are isolated after being induced in an animal host by intralesional (IL) administration of a halogenated xanthene tumor-ablative compound into a solid cancerous tumor of that host animal. A sample of the induced immune anticancer agents is removed (collected) from the tumor-bearing host, banked if desired, cultured and preferentially expanded to form an immunologically-effective enriched tumor-specific immune anticancer agent composition. That composition is reintroduced in to the host from which the predecessor induced immune anticancer agents were taken, or into another immunologically suitable host in need.Type: ApplicationFiled: December 18, 2015Publication date: June 22, 2017Applicant: PROVECTUS PHARMATECH, INC.Inventors: Jamie Singer, Eric Wachter, Amod Sarnaik, Shari Pilon-Thomas, Hao Liu
-
Patent number: 9422260Abstract: A new process for the manufacture of iodinated xanthenes in high purity includes a cyclization step followed by an iodination step. No extraction, chromatographic or solvent concentration steps are required, and the intermediate as well as final compounds are isolated via filtration or similar means. The process requires a single organic solvent, and the steps are completed at temperatures below 100° C. The exclusion of chloride ions, of chloride free-radicals, hypochlorite ions, or hypochlorous acid as reagents or from reagents that may generate these species in situ in the presence of oxidants, prevents undesirable impurity formation. Several new compounds have been conceived and isolated using these methods. These new compounds are also formed into new medicaments.Type: GrantFiled: June 12, 2013Date of Patent: August 23, 2016Assignee: PROVECTUS PHARMATECH, INC.Inventors: Jamie Singer, Eric A. Wachter, Timothy Scott, Marlon Lutz, Kevin Babiak
-
Patent number: 9273022Abstract: A new process for the manufacture of iodinated xanthenes in high purity includes a cyclization step followed by an iodination step. No extraction, chromatographic or solvent concentration steps are required, and the intermediate as well as final compounds are isolated via filtration or similar means. The process requires a single organic solvent, and the steps are completed at temperatures below 100° C. The exclusion of chloride ions, of chloride free-radicals, hypochlorite ions, or hypochlorous acid as reagents or from reagents that may generate these species in situ in the presence of oxidants, prevents undesirable impurity formation. Several new compounds have been conceived and isolated using these methods. These new compounds are also formed into new medicaments.Type: GrantFiled: July 30, 2014Date of Patent: March 1, 2016Assignee: Provectus Pharmaceuticals, Inc.Inventors: Jamie Singer, Eric A. Wachter, Timothy Scott, Marlon Lutz, Kevin Babiak, Sahadeva Reddy Damireddi, J. Robert Durrwachter
-
Publication number: 20150290318Abstract: A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.Type: ApplicationFiled: June 24, 2015Publication date: October 15, 2015Applicants: Provectus Pharmaceuticals, Inc., Pfizer, Inc.Inventors: Craig J. Eagle, H. Craig Dees, Eric A. Wachter, Jamie Singer
-
Publication number: 20150290309Abstract: A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.Type: ApplicationFiled: June 24, 2015Publication date: October 15, 2015Applicant: Provectus Pharmaceuticals, Inc.Inventors: H. Craig Dees, Eric A. Wachter, Jamie Singer
-
Publication number: 20150290165Abstract: A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.Type: ApplicationFiled: June 24, 2015Publication date: October 15, 2015Applicants: Provectus Pharmaceuticals, Inc., Pfizer, Inc.Inventors: Craig J. EAGLE, H. Craig DEES, Eric A. WACHTER, Jamie SINGER